Miller, L; Mueller, M. What is the evidence and rationale describing the key public health principles to consider for school re-openings and precautions regarding school closures during COVID-19? 2020 Jul 13; Document no.: EOC070901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc130
Miller, L; Mueller, M. What is the evidence and rationale describing the key public health principles to consider for school re-openings and precautions regarding school closures during COVID-19? 2020 Aug 6; Document no.: EOC070901v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 25 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc142
Dalidowicz, M; Ellsworth, C. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 7; Document no.: EOC070201v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 29 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc143
Sulaiman, F; Groot, G; Muhajarine, N; Dalidowicz, M; Miller, L. What is the transmissibility and epidemiology of COVID-19 in children and adolescents? 2020 Aug 14; Document no.: EOC070201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc149
Badea, A; Muhajarine, N; Reeder, B; Miller, L; Mueller, M. What is the evidence and rationale describing the key public health principles to consider for school re-openings and precautions regarding school closures during COVID-19? 2020 Aug 17; Document no.: EOC070901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc154
Dalidowicz, M; Fox, L. What is the post acute covid syndrome and its implications in terms of health services? 2020 Sep 18; Document no.: EOC091601-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 40 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc181
Badea, A; Groot, G; Dalidowicz, M; Fox, L. What is the post acute covid syndrome and its implications in terms of health services? 2020 Oct 13; Document no.: EOC091601 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 28 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc192
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc232
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc248
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST table) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc261
Miller, L; Howell-Spooner, B. What are the differences between COVID-19 vaccines and how should they be distributed based on population group(s)? 2021 Mar 11; Document no.: EOC031001-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc275
Azizian, A; Shumilak, G; Lee, S; Reeder, B; Groot, G; Miller, L; Howell-Spooner, B. What are the differences between COVID-19 vaccines and how they should be distributed based on population group(s)? 2021 Mar 18; Document no.: EOC031001 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 19 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc279
Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 01; Document no.: EOC210302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc289
Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 15 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc299
Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc300
Miller, L., Howell-Spooner, B. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Sep 29, Document no.: EOC210902 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc375
What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? No citation available. https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc381
Badea, A; Groot, G; Muhajarine, N; Lee, S; Shumilak, G; Hernandez-Ronquillo, L; Tian, K. What is the current evidence and recommendations regarding COVID-19 vaccine booster shots (exceeding 2 doses) for the general population? 2021 Oct 07, Document no.: EOC210902 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 8 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc383
Miller, L. (Update) What are the recommendations around settling times following aerosol generating procedures on suspected or confirmed COVID-19 patients? 2020 Nov 27; Document no.: EOC081401v2-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc213
Badea, A; Groot G; Dalidowicz, M; Young, C; Miller, L. What are the recommendations around settling times following aerosol generating procedures on suspected or confirmed COVID-19 patients? 2020 Dec 1; Document no.: EOC081401v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 24 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc214
